IBRX

NASDAQ Healthcare

ImmunityBio, Inc. - Common Stock

Biotechnology

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guรฉrin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

๐Ÿ“Š Market Data
Price$7.11
Volume7,618,968
Market Cap7.34B
Beta0.060
RSI (14-Day)47.4
200-Day MA$4.30
50-Day MA$8.13
52-Week High$12.43
52-Week Low$1.83
Forward P/E-355.50
Price / Book-14.36
๐ŸŽฏ Investment Strategy Scores

IBRX scores across each investment strategy. Higher is better for that strategy's goals.

๐Ÿ’ฐ Dividend Daddy 51/100โ–ฒ +1
High dividend yield + low volatility
๐Ÿš€ Moon Shot 17/100โ–ฒ +1
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 17/100โ€” 0
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 29/100โ–ฒ +5
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐Ÿ‹ Institutional Whale (67/100) โ€” this strategy Large-cap, institutional-quality stocks.

Lowest fit among scored strategies: ๐Ÿ”ช Falling Knife (17/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find IBRX in your text

Paste any article, transcript, or post โ€” the tool will extract IBRX and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.